Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Jan 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms NADIM

17 Jan 2024 Status changed from active, no longer recruiting to completed.
06 Jun 2023 Results (n=42) assessing the changes in B cell peripheral blood immunophenotype during perioperative immunotherapy and its potential to predict disease progression in patients with non-small cell lung cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
09 Jan 2023 Planned End Date changed from 30 Jun 2023 to 30 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com